Or call us at 1-877-219-7770
Add Your Heading Text Here
Enroll eligible patients
Help your patients get treatment support
Start your patients on their treatment journey with comprehensive support services from Madrigal Patient Support®.
Choose which option works best for your practice to help your patient get enrolled.
Patient Authorization Form
Send the prescription to an in-network specialty pharmacy and submit the completed Patient Authorization Form to Madrigal Patient Support. This ensures patients are enrolled from the start and gives them access to financial assistance, nurse support, and ongoing education. A Patient Authorization Form must be signed by the patient.
You can also ask your Madrigal Field Representative for a copy or call us directly at 1-877-219-7770.
More ways to enroll your patients
When you submit a prescription to an in-network specialty pharmacy, you can also submit the Patient Authorization Form at the same time.
e-prescribing Rezdiffra® (resmetirom) using CoAssist Pharmacy
CoAssist integrates directly with Madrigal Patient Support through your EHR. With just one eRx, you can automatically send an e-consent
text to your patient to enroll them in Madrigal Patient Support.
Send the eRx to CoAssist Pharmacy NCPDP: 5733604
Be sure to include the patient's weight, diagnosis code and
specify whether it’s a Bridge or Commercial prescription in
the pharmacy notes section.
Enrollment Form
Use the Enrollment Form if your patient may need access to the Bridge Program or Patient Assistance Program or if your office needs prior authorization support from Madrigal Patient Support.
Access the Enrollment Form using one of these options:
Once enrolled, patients can expect a welcome call
Once a patient has been enrolled, their dedicated Case Manager will call them within a few days to:
- provide an overview of the program
- inform them about coverage and/or potential financial assistance options for their medication
- share available resources
- answer questions they may have to help them get started
You may want to let your patient know to expect a call from Madrigal Patient Support.
Indication and Important Safety Information
Indication
Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Limitation of Use: Avoid use in patients with decompensated cirrhosis.
WARNINGS AND PRECAUTIONS
Hepatotoxicity
Hepatotoxicity has been observed with the use of Rezdiffra. One patient developed substantial elevations of liver biochemistries that resolved when treatment was interrupted. Please see full Prescribing Information for more details on this specific case of Hepatotoxicity [see Warnings and Precautions (5.1)].
Monitor for elevations in liver tests, liver-related adverse reactions, and symptoms/signs of hepatotoxicity (eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, fever, rash, and/or eosinophilia [>5%]). If hepatotoxicity is suspected, discontinue Rezdiffra and monitor. If laboratory values return to baseline, weigh the potential risks against the benefits of restarting Rezdiffra. If laboratory values do not return to baseline, consider druginduced autoimmune-like hepatitis (DI-ALH) or autoimmune liver disease in the evaluation of elevations in liver tests.
Gallbladder-Related Adverse Reactions
Cholelithiasis, acute cholecystitis, and obstructive pancreatitis (gallstone) were observed more often in Rezdiffratreated patients than in placebo-treated patients. The exposure-adjusted incidence rates (EAIRs) for these events were
less than 1 per 100 person-years (PY) for all treatment arms. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. If an acute gallbladder event is suspected, interrupt treatment until the event is resolved.
Drug Interaction with Certain Statins
An increase in exposure of atorvastatin, pravastatin, rosuvastatin, and simvastatin was observed when concomitantly administered with Rezdiffra, which may increase the risk of adverse reactions related to these drugs.
Dosage adjustment for certain statins is recommended. Monitor for statin-related adverse reactions including, but not limited to, elevation of liver tests, myopathy, and rhabdomyolysis.
ADVERSE REACTIONS
The most common adverse reactions with Rezdiffra (reported in ≥5% of patients and higher compared to placebo) are diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness. Diarrhea and nausea were the most common causes of treatment discontinuation.
DRUG INTERACTIONS
Clinically Significant Interaction Effects of Strong or Moderate CYP2C8 Inhibitors on Rezdiffra
- Concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil) is not recommended. Reduce Rezdiffra dosage if used concomitantly with a moderate CYP2C8 inhibitor (eg, clopidogrel).
Clinically Significant Interactions Affecting Other Drugs
- Statins: Limit daily rosuvastatin and simvastatin dosage to 20 mg. Limit pravastatin and atorvastatin dosage to 40 mg.
- CYP2C8 Substrates: Monitor patients more frequently for substrate-related adverse reactions if Rezdiffra is coadministered with CYP2C8 substrates where minimal concentration changes may lead to serious adverse reactions.
USE IN SPECIFIC POPULATIONS
Pregnancy
There are no available data on Rezdiffra use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Madrigal Pharmaceuticals, Inc. Adverse Event Reporting line at 1-800-905-0324 and visit https://pregnancyregistry.madrigalpharma.com for information about a pregnancy safety study.
Lactation
There is no information regarding the presence of Rezdiffra in human or animal milk, the effects on the breast-fed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Rezdiffra and any potential adverse effects on the breastfed infant from Rezdiffra or from the underlying maternal condition.
Geriatric Use
Numerically higher incidence of adverse reactions have been observed in patients ≥65 years of age compared to younger adult patients.
Renal Impairment
The recommended dosage of Rezdiffra in patients with mild, moderate, or severe renal impairment is the same as in patients with normal kidney function.
Hepatic Impairment
Avoid use in patients with decompensated cirrhosis (consistent with moderate to severe hepatic impairment). Moderate or severe hepatic impairment (Child-Pugh Class B or C) may increase the risk of adverse reactions.
The safety and effectiveness of Rezdiffra have not been established in patients with cirrhosis.
Please see full Prescribing Information for Rezdiffra.